Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Forventet)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: yi ba, PhD
- Telefonnummer: 13752157916
- E-post: bayi@timuch.com
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 1.Prior to any detailed procedures of this study, subjects are able to understand, voluntarily participate in and sign the informed consent approved by the ethics committee.
- 2.Age ≥ 18 years.
- 3.Histologically confirmed, unresectable, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma .
- 4.Have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.
- 5.Have experienced documented objective radiographic or symptomatic disease progression during first-line therapy, or within 4 months after the last dose of first-line therapy with any platinum or/and fluoropyrimidine doublet for unresectable or metastatic disease.Second line chemotherapy is suitable for paclitaxel.
- 6.Laboratory test values must meet the following criteria. ANC ≥1.5×109/L, platelets ≥ 100×109/L, hemoglobin≥9g/dL. Blood creatinine ≤ 1.5 ×ULN or creatinine clearance ≥ 50 mL/min/m2. Total bilirubin ≤ 1.5× ULN(≤ 3 x ULN if Gilbert disease), AST and ALT ≤ 2.5× ULN (≤ 5×ULN if hepatic metastasis).
INR ≤ 1.5× ULN, APTT ≤ 1.5× ULN. Dipstick proteinuria <2+ or 24 hour proteinuria <1g .
- 7.Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1.
- 8.Life expectancy of ≥ 3 months.
Exclusion Criteria:
- 1.Histologically confirmed squamous cell carcinoma or undifferentiated gastric cancer.
- 2.Patients with disease progression within 6 months after previous adjuvant or neoadjuvant chemotherapy with paclitaxel, or patients with recurrent or metastatic gastric adenocarcinoma or GEJ adenocarcinoma treated with paclitaxel.
- 3. GI perforation and/or fistulae in the 6 months preceding randomization.
- 4.Deep-vein thrombosis, pulmonary embolism (PE), or any other episode of Uncontrolled thromboembolism in the 6 months preceding randomization.
- 5.Any arterial thromboembolic event (such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack)
- 6.Uncontrolled hypertension (≥150/100 mm Hg ) despite properly observed antihypertensive therapy.
- 7.Known brain metastasis.
- 8.Known allergy to paclitaxel or KH903.
- 9.Serious concurrent infection or medical illness.
- 10.Active hepatitis B virus or Active hepatitis C virus (HCV) infection at screening.
- 11.Any condition which results in an undue risk for the patient during the trial participation according to the investigator.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: KH903 + Paclitaxel
IV KH903 4 mg/kg IV paclitaxel 80 mg/m²
|
KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle; Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
|
|
Aktiv komparator: Placebo + Paclitaxel
IV Placebo IV paclitaxel 80 mg/m²
|
Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle; Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival(PFS)
Tidsramme: Time from date of randomization until the date of first documented Progression or date of death from any cause, whichever came frist,assessed up to18 months
|
Date of randomization until the date of first documented Progression or date of death from any cause, whichever came first
|
Time from date of randomization until the date of first documented Progression or date of death from any cause, whichever came frist,assessed up to18 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR)
Tidsramme: Time from date of randomization until the date of first documented CR or PR,assessed up to18 months
|
Percentage of Participants with a Best Overall Response (BOR) of Partial Response (PR) or Complete Response (CR)
|
Time from date of randomization until the date of first documented CR or PR,assessed up to18 months
|
|
Duration of Response (DOR)
Tidsramme: Time from first documented evidence of CR or PR until the date of first documented progression ,assessed up to18 months
|
is defined as the time from first documented evidence of CR or PR until the date of first documented progression as assessed by RECIST 1.1 or death; assessed up to18 months
|
Time from first documented evidence of CR or PR until the date of first documented progression ,assessed up to18 months
|
|
Disease Control Rate (DCR)
Tidsramme: Time from date of randomization until the date of first documented Progression,assessed up to18 months
|
Percentage of Participants who have achieved CR, PR and SD to study treatment;
|
Time from date of randomization until the date of first documented Progression,assessed up to18 months
|
|
AE
Tidsramme: AEs(NCI CTCAE 5.0) collected at each cycle,Assessed up to18 months
|
Number of Subjects with treatment-related adverse events (AEs)Defined by all
|
AEs(NCI CTCAE 5.0) collected at each cycle,Assessed up to18 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: yi ba, PhD, Tianjin Medical University Cancer Institute and Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Studiestart
Primær fullføring (Forventet)
Primær fullføring
Studiet fullført (Forventet)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Karsinom
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Paklitaksel
- Albuminbundet paklitaksel
Andre studie-ID-numre
Andre studie-ID-numre
- KH903-40101-CRP
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .